Table 1 Clinical Characteristics of the LGG Sample Set According to RNA subtypes
From: Radiogenomics correlation between MR imaging features and mRNA-based subtypes in lower-grade glioma
|  | Total (N = 145) | RNAR1 | RNAR2 | RNAR3 | RNAR4 | ||||
|---|---|---|---|---|---|---|---|---|---|
(−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | ||
Histological type — no. (%) | |||||||||
 Oligodendroglioma | 65 (44.83) | 51 (49.04) | 14 (34.15) | 58 (55.24) | 7 (17.5) | 49 (38.89) | 16 (84.21) | 37 (37) | 28 (62.22) |
 Astrocytoma | 49 (33.79) | 36 (34.62) | 13 (31.71) | 21 (20) | 28 (70) | 48 (38.1) | 1 (5.26) | 42 (42) | 7 (15.56) |
 Oligoastrocytoma | 31 (21.38) | 17 (16.35) | 14 (34.15) | 26 (24.76) | 5 (12.5) | 29 (23.02) | 2 (10.53) | 21 (21) | 10 (22.22) |
Neoplasm histologic grade — no. (%) | |||||||||
 G2 | 71 (48.97) | 42 (40.38) | 29 (70.73) | 64 (60.95) | 7 (17.5) | 64 (50.79) | 7 (36.84) | 43 (43) | 28 (62.22) |
 G3 | 74 (51.03) | 62 (59.62) | 12 (29.27) | 41 (39.05) | 33 (82.5) | 62 (49.21) | 12 (63.16) | 57 (57) | 17 (37.78) |
Age at diagnosis— yr | |||||||||
 Mean | 44.06 ± 13.78 | 46.46 ± 13.69 | 37.98 ± 12.18 | 41.83 ± 13.09 | 49.93 ± 13.98 | 42.72 ± 13.63 | 52.95 ± 11.53 | 45.6 ± 14.25 | 40.64 ± 12.15 |
 Range | 18–75 | 20–75 | 18–70 | 18–75 | 23–70 | 18–70 | 30–75 | 18–75 | 20–67 |
Gender — no. (%) | |||||||||
 Female | 70 (48.28) | 52 (50) | 18 (43.9) | 49 (46.67) | 21 (52.5) | 61 (48.41) | 9 (47.37) | 48 (48) | 22 (48.89) |
 Male | 75 (51.72) | 52 (50) | 23 (56.1) | 56 (53.33) | 19 (47.5) | 65 (51.59) | 10 (52.63) | 52 (52) | 23 (51.11) |
Race — no. (%) | |||||||||
 American Indian or Alaska Native | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 Black or African American | 8 (5.56) | 5 (4.81) | 3 (7.5) | 6 (5.77) | 2 (5) | 8 (6.4) | 0 (0) | 5 (5.05) | 3 (6.67) |
 White | 136 (94.44) | 99 (95.19) | 37 (92.5) | 98 (94.23) | 38 (95) | 117 (93.6) | 19 (100) | 94 (94.95) | 42 (93.33) |
Family history of cancer — no. (%) | |||||||||
 No | 60 (55.05) | 37 (48.05) | 23 (71.88) | 47 (58.02) | 13 (46.43) | 55 (56.7) | 5 (41.67) | 41 (56.94) | 19 (51.35) |
 Yes | 49 (44.95) | 40 (51.95) | 9 (28.13) | 34 (41.98) | 15 (53.57) | 42 (43.3) | 7 (58.33) | 31 (43.06) | 18 (48.65) |
Method of sample procuremen — no. (%) | |||||||||
 Open biopsy | 5 (3.45) | 4 (3.85) | 1 (2.44) | 3 (2.86) | 2 (5) | 5 (3.97) | 0 (0) | 3 (3) | 2 (4.44) |
 Subtotal resection | 45 (31.03) | 33 (31.73) | 12 (29.27) | 30 (28.57) | 15 (37.5) | 38 (30.16) | 7 (36.84) | 34 (34) | 11 (24.44) |
 Gross total resection | 95 (65.52) | 67 (64.42) | 28 (68.29) | 72 (68.57) | 23 (57.5) | 83 (65.87) | 12 (63.16) | 63 (63) | 32 (71.11) |
First presenting symptom — no. (%) | |||||||||
 Headaches | 35 (25) | 20 (19.8) | 15 (38.46) | 28 (27.72) | 7 (17.95) | 32 (26.23) | 3 (16.67) | 25 (26.04) | 10 (22.73) |
 Mental status change | 11 (7.86) | 9 (8.91) | 2 (5.13) | 8 (7.92) | 3 (7.69) | 8 (6.56) | 3 (16.67) | 8 (8.33) | 3 (6.82) |
 Motor or movement change | 9 (6.43) | 8 (7.92) | 1 (2.56) | 6 (5.94) | 3 (7.69) | 7 (5.74) | 2 (11.11) | 6 (6.25) | 3 (6.82) |
 Seizure | 79 (56.43) | 58 (57.43) | 21 (53.85) | 55 (54.46) | 24 (61.54) | 71 (58.2) | 8 (44.44) | 53 (55.21) | 26 (59.09) |
 Sensory or visual change | 6 (4.29) | 6 (5.94) | 0 (0) | 4 (3.96) | 2 (5.13) | 4 (3.28) | 2 (11.11) | 4 (4.17) | 2 (4.55) |
Laterality — no. (%) | |||||||||
 Left | 70 (48.61) | 49 (47.57) | 21 (51.22) | 51 (49.04) | 19 (47.5) | 63 (50.4) | 7 (36.84) | 47 (47) | 23 (52.27) |
 Midline | 3 (2.08) | 3 (2.91) | 0 (0) | 1 (0.96) | 2 (5) | 2 (1.6) | 1 (5.26) | 3 (3) | 0 (0) |
 Right | 71 (49.31) | 51 (49.51) | 20 (48.78) | 52 (50) | 19 (47.5) | 60 (48) | 11 (57.89) | 50 (50) | 21 (47.73) |
IDH/1p19q Subtype | |||||||||
 IDHmut-non-codel | 70 (48.95) | 31 (30.1) | 39 (97.5) | 59 (57.28) | 11 (27.5) | 70 (56) | 0 (0) | 50 (51.02) | 20 (44.44) |
 IDHmut-codel | 35 (24.48) | 35 (33.98) | 0 (0) | 35 (33.98) | 0 (0) | 17 (13.6) | 18 (100) | 18 (18.37) | 17 (37.78) |
 IDHwt | 38 (26.57) | 37 (35.92) | 1 (2.5) | 9 (8.74) | 29 (72.5) | 38 (30.4) | 0 (0) | 30 (30.61) | 8 (17.78) |